XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study
December 02, 2021 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Dec. 02, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on...
XORTX Therapeutics Announces Annual and Special Meeting of Shareholders
November 23, 2021 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing...
XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering
November 09, 2021 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 09, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing...
XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange
November 04, 2021 14:49 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing...
XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange
November 02, 2021 18:13 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Nov. 02, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing...
XORTX Therapeutics Announces Closing of US$12 Million Public Offering
October 15, 2021 17:38 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 15, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing...
XORTX Announces Results from Mount Sinai’s COVID-19 Clinical Study
October 14, 2021 17:30 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 14, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing...
XORTX to Present at the LD Micro Main Event
October 14, 2021 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 14, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing...
XORTX Therapeutics Announces Pricing of US$12 Million Public Offering and Nasdaq Listing
October 13, 2021 07:55 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 13, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing...
XORTX Therapeutics Announces Share Consolidation
September 20, 2021 16:46 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 20, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing...